Movano Inc. (NASDAQ:MOVE) Short Interest Down 41.4% in January
by Mitch Edgeman · The Markets DailyMovano Inc. (NASDAQ:MOVE – Get Free Report) was the target of a large decrease in short interest in January. As of January 15th, there was short interest totaling 25,442 shares, a decrease of 41.4% from the December 31st total of 43,438 shares. Currently, 3.4% of the company’s shares are short sold. Based on an average trading volume of 29,466 shares, the days-to-cover ratio is currently 0.9 days. Based on an average trading volume of 29,466 shares, the days-to-cover ratio is currently 0.9 days. Currently, 3.4% of the company’s shares are short sold.
Analyst Ratings Changes
A number of brokerages recently issued reports on MOVE. Wall Street Zen cut shares of Movano from a “hold” rating to a “sell” rating in a report on Saturday, January 17th. Weiss Ratings reiterated a “sell (e+)” rating on shares of Movano in a research note on Thursday, January 22nd. One research analyst has rated the stock with a Sell rating, According to MarketBeat, the stock has an average rating of “Sell”.
Get Our Latest Research Report on Movano
Key Movano News
Here are the key news stories impacting Movano this week:
- Positive Sentiment: Institutional interest: Citadel Advisors bought a new, material position (~49,262 shares, ~5.94% of outstanding in the most recent 13F), which can provide buying support and signal that a major manager sees value. MarketBeat — Movano profile
- Positive Sentiment: Short interest declined sharply in early January (~41% fall from Dec. 31 to Jan. 15), reducing the pool of bearish bets and lowering the chance of a short‑squeeze–driven rebound.
- Positive Sentiment: Technical: shares recently cleared the 200‑day moving average, a bullish technical milestone that can attract momentum traders. Article: Movano Shares Pass Above 200-Day Moving Average
- Neutral Sentiment: Volume and liquidity: today’s trading volume is well below the stock’s longer‑term average, so price moves may be amplified by lighter order flow.
- Neutral Sentiment: Macro pressure: U.S. equities are under pressure amid renewed inflation concerns, a headwind for speculative and small‑cap names like MOVE. RTTNews — U.S. stocks move to the downside
- Negative Sentiment: CEO insider sale: John Mastrototaro sold 33,069 shares (~37% reduction in his stake) at about $20.80 — a sizable executive exit that often spooks investors. Filing: CEO SEC filing
- Negative Sentiment: CFO insider sale: Jeremy Cogan sold 28,736 shares (~32% reduction) at about $20.78; additional recent sales by the CFO increase investor concern about insider confidence. Filing: CFO SEC filing
- Negative Sentiment: Operational fundamentals: while Movano beat EPS estimates in its last print, revenue was far below expectations ($0.08M actual vs. ~$3.88M expected) and the company shows very large negative margins and negative ROE — fundamentals remain stressed and justify a cautious view. MarketBeat — Movano earnings summary
Insider Activity at Movano
In related news, CFO Jeremy Cogan sold 28,736 shares of the business’s stock in a transaction that occurred on Tuesday, January 27th. The shares were sold at an average price of $20.78, for a total transaction of $597,134.08. Following the transaction, the chief financial officer directly owned 60,504 shares of the company’s stock, valued at approximately $1,257,273.12. The trade was a 32.20% decrease in their ownership of the stock. The sale was disclosed in a document filed with the SEC, which is accessible through the SEC website. Also, CEO John Mastrototaro sold 33,069 shares of the business’s stock in a transaction on Tuesday, January 27th. The shares were sold at an average price of $20.80, for a total transaction of $687,835.20. Following the transaction, the chief executive officer owned 56,114 shares in the company, valued at approximately $1,167,171.20. This represents a 37.08% decrease in their ownership of the stock. The disclosure for this sale is available in the SEC filing. In the last 90 days, insiders sold 94,383 shares of company stock worth $1,524,933. 10.40% of the stock is owned by corporate insiders.
Institutional Investors Weigh In On Movano
An institutional investor recently bought a new position in Movano stock. Citadel Advisors LLC bought a new position in Movano Inc. (NASDAQ:MOVE – Free Report) in the third quarter, according to its most recent disclosure with the Securities and Exchange Commission (SEC). The fund bought 49,262 shares of the technology company’s stock, valued at approximately $28,000. Citadel Advisors LLC owned about 5.94% of Movano at the end of the most recent quarter. 16.64% of the stock is owned by institutional investors and hedge funds.
Movano Trading Down 7.1%
MOVE stock traded down $1.35 during midday trading on Friday, hitting $17.72. The stock had a trading volume of 115,185 shares, compared to its average volume of 2,895,524. The firm has a market capitalization of $14.80 million, a price-to-earnings ratio of -1.64 and a beta of 0.79. The stock has a 50-day simple moving average of $9.43 and a 200 day simple moving average of $7.97. Movano has a 52 week low of $4.67 and a 52 week high of $55.00.
Movano (NASDAQ:MOVE – Get Free Report) last announced its quarterly earnings results on Friday, November 14th. The technology company reported ($4.73) EPS for the quarter, topping analysts’ consensus estimates of ($7.00) by $2.27. The firm had revenue of $0.08 million during the quarter, compared to analysts’ expectations of $3.88 million. Movano had a negative net margin of 3,409.60% and a negative return on equity of 647.91%.
Movano Company Profile
Movano Health, Inc (NASDAQ: MOVE) is a health technology company focused on developing wearable devices for continuous biometric monitoring. The company’s core mission is to provide accessible, real-time health insights through noninvasive sensors, enabling individuals and care teams to track vital signs and physiological trends outside of traditional clinical settings.
Movano’s flagship product is a biometric monitoring ring designed to measure parameters such as heart rate, blood oxygen saturation, skin temperature, and sleep quality.